ATE478657T1 - Verwendung von synthetischen anorganischen nanoteilchen als träger für augenmedikamente - Google Patents
Verwendung von synthetischen anorganischen nanoteilchen als träger für augenmedikamenteInfo
- Publication number
- ATE478657T1 ATE478657T1 AT02806507T AT02806507T ATE478657T1 AT E478657 T1 ATE478657 T1 AT E478657T1 AT 02806507 T AT02806507 T AT 02806507T AT 02806507 T AT02806507 T AT 02806507T AT E478657 T1 ATE478657 T1 AT E478657T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- carriers
- nanoparticles
- inorganic nanoparticles
- synthetic inorganic
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 239000000969 carrier Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 239000011147 inorganic material Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910021647 smectite Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34298301P | 2001-12-21 | 2001-12-21 | |
PCT/US2002/041248 WO2003059194A2 (en) | 2001-12-21 | 2002-12-20 | Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE478657T1 true ATE478657T1 (de) | 2010-09-15 |
Family
ID=23344163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02806507T ATE478657T1 (de) | 2001-12-21 | 2002-12-20 | Verwendung von synthetischen anorganischen nanoteilchen als träger für augenmedikamente |
Country Status (19)
Country | Link |
---|---|
US (2) | US20050003014A1 (de) |
EP (1) | EP1474109B1 (de) |
JP (1) | JP2005514429A (de) |
KR (1) | KR100990810B1 (de) |
CN (1) | CN100441169C (de) |
AT (1) | ATE478657T1 (de) |
AU (1) | AU2002367029B2 (de) |
BR (1) | BR0215238A (de) |
CA (1) | CA2467763C (de) |
DE (1) | DE60237475D1 (de) |
DK (1) | DK1474109T3 (de) |
ES (1) | ES2349235T3 (de) |
HK (1) | HK1075001A1 (de) |
MX (1) | MXPA04004919A (de) |
PL (1) | PL211494B1 (de) |
PT (1) | PT1474109E (de) |
SI (1) | SI1474109T1 (de) |
WO (1) | WO2003059194A2 (de) |
ZA (1) | ZA200403666B (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04005227A (es) | 2001-12-21 | 2004-10-11 | Alcon Inc | Uso de nanoparticulas como portadores para biocidas en composiciones oftalmicas. |
PL211494B1 (pl) | 2001-12-21 | 2012-05-31 | Alcon | Zastosowanie syntetycznych, nieorganicznych nanocząstek jako nośników dla leków i kompozycja farmaceutyczna do oczu lub uszu |
WO2003059263A2 (en) * | 2001-12-21 | 2003-07-24 | Alcon, Inc. | Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions. |
WO2004066975A1 (en) | 2002-12-18 | 2004-08-12 | Hough Ear Institute | Otologic nanotechnology |
US8651113B2 (en) | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7344491B1 (en) | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
US7723311B2 (en) | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
EP2112196A1 (de) * | 2008-04-25 | 2009-10-28 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Flüssige Zusammensetzung mit Polymerketten und Partikeln aus einem anorganischen Material in einer Flüssigkeit |
US20100098768A1 (en) * | 2008-10-16 | 2010-04-22 | Clarkson University | Method of neuroprotection from oxidant injury using metal oxide nanoparticles |
EP2600901B1 (de) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
EP2611466B1 (de) | 2010-08-30 | 2019-06-12 | President and Fellows of Harvard College | Scherungsgesteuerte freisetzung von thrombolytischen therapien für stenoseläsionen |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151666A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
KR101415221B1 (ko) * | 2012-08-07 | 2014-07-09 | 한국표준과학연구원 | 무기 나노입자를 유효성분으로 함유하는 혈관 신생 관련 질환의 예방 및 치료용 조성물 |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CL2013003807A1 (es) * | 2013-12-31 | 2014-07-11 | Univ Santiago Chile | Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol. |
EP3169693B1 (de) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimäre polynukleotide |
EP3171895A1 (de) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von intrabodys |
ES2951202T3 (es) | 2014-07-28 | 2023-10-19 | Sun Pharma Advanced Res Co Ltd | Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco |
MY189159A (en) | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
SI3394093T1 (sl) | 2015-12-23 | 2022-05-31 | Modernatx, Inc. | Metode uporabe liganda OX40, ki kodira polinukleotid |
WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
WO2018053273A1 (en) | 2016-09-15 | 2018-03-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Shear-thinning therapeutic composition, and related methods |
AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
CN109045305B (zh) * | 2018-07-31 | 2021-12-10 | 东华大学 | 一种tpgs修饰的锂皂石纳米颗粒的制备方法 |
CA3125511A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
EP3851097A1 (de) * | 2020-01-15 | 2021-07-21 | Universidad De Zaragoza | Retard-formulierungen |
EP4172194A1 (de) | 2020-07-31 | 2023-05-03 | CureVac SE | Nukleinsäurecodierte antikörpermischungen |
JPWO2022059736A1 (de) | 2020-09-17 | 2022-03-24 | ||
US20230355540A1 (en) | 2020-09-29 | 2023-11-09 | Oxford University Innovation Limited | Stroke treatment |
WO2023133579A1 (en) | 2022-01-10 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Bbb-targeted gaa delivered as gene therapy treats cns and muscle in pompe disease model mice |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US627124A (en) * | 1899-06-20 | Fan attachment for sewing-machines | ||
US3947573A (en) | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
US3884826A (en) * | 1973-07-20 | 1975-05-20 | Barnes Hind Pharm Inc | Thixotropic cleaning agent for hard contact lenses |
US3974125A (en) * | 1974-09-27 | 1976-08-10 | Exxon Research And Engineering Company | Higher dialkyl dimethyl ammonium clay gelling agents for unsaturated polyester compositions |
US4127423A (en) * | 1977-09-13 | 1978-11-28 | Burton, Parsons And Company, Inc. | Contact lens cleaning solution |
US4120949A (en) | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4394179A (en) * | 1979-06-25 | 1983-07-19 | Polymer Technology Corporation | Abrasive-containing contact lens cleaning materials |
US4374745A (en) * | 1981-08-13 | 1983-02-22 | Barnes-Hind Pharmaceuticals, Inc. | Cleaning compositions |
US4940701A (en) * | 1984-01-25 | 1990-07-10 | Beecham Group P.L.C. | Topical drug release system |
GB8401965D0 (en) * | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
EP0217440A1 (de) * | 1985-09-27 | 1987-04-08 | The Procter & Gamble Company | Stabile wässrige pharmazeutische Suspensionen |
US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
WO1988004168A1 (en) * | 1986-12-08 | 1988-06-16 | Arseco, Inc. | A storage stable topical composition |
US4847078A (en) * | 1987-01-14 | 1989-07-11 | Arseco, Inc. | Storage stable topical composition having moisture control agent |
JPH01501899A (ja) | 1986-12-24 | 1989-06-29 | アルコン ラボラトリーズ インコーポレイテッド | コンタクトレンズ用洗浄剤及びその使用方法 |
US4891043A (en) * | 1987-05-28 | 1990-01-02 | Board Of Trustees Of The University Of Illinois | System for selective release of liposome encapsulated material via laser radiation |
US4923699A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Eye treatment suspension |
US5037647A (en) * | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
US5674504A (en) * | 1989-07-12 | 1997-10-07 | L'oreal | Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
US5212162A (en) * | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
JP2536806B2 (ja) * | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
EP0546728A3 (en) * | 1991-12-13 | 1993-09-08 | Alcon Laboratories Inc | Physiological tear compositions and methods for their preparation |
US5139782A (en) * | 1991-12-23 | 1992-08-18 | Uop | Facial cleansing mineral compositions |
US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
ATE365530T1 (de) * | 1992-07-13 | 2007-07-15 | Shiseido Co Ltd | Retinolthaltiges, stabilisiertes hautpflegemittel zur äusserlichen anwendung |
US5532224A (en) * | 1993-12-22 | 1996-07-02 | Alcon Laboratories, Inc. | Contact lens cleaning composition containing polyalklene oxide modified siloxanes |
WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
CN1155383C (zh) * | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途 |
JP3736916B2 (ja) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの消毒用組成物とその用途 |
US6015816A (en) * | 1996-02-29 | 2000-01-18 | The Research Foundation Of State University Of New York | Antimicrobial compositions |
ES2161473T3 (es) * | 1996-09-20 | 2001-12-01 | Bausch & Lomb | Metodo y composicion para rehumedecer lentes de contacto y aliviar la sequedad ocular. |
US5811580A (en) * | 1996-12-04 | 1998-09-22 | The Lubrizol Corporation | Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts |
DE69713388T2 (de) * | 1996-12-13 | 2002-10-31 | Alcon Lab Inc | Verwendung von niedermolekularen aminoalkoholen in ophthalmologischen präparaten |
US5858346A (en) * | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
CA2296080C (en) * | 1997-07-29 | 2005-02-01 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
DE69806498T2 (de) | 1997-11-12 | 2003-01-16 | Bausch & Lomb | Behandlung von kontaktlinsen mit wässrigen, alkalicarbonat-haltigen lösungen |
ZA9811445B (en) | 1997-12-19 | 1999-08-16 | Alcon Lab Inc | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions. |
JPH11281937A (ja) * | 1998-03-27 | 1999-10-15 | Menicon Co Ltd | コンタクトレンズ用剤 |
US20010016577A1 (en) * | 1998-08-24 | 2001-08-23 | Douglas Joseph Dobrozsi | Oral mucoadhesive compositions containing gastrointestinal actives |
US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
FR2783419B1 (fr) | 1998-09-18 | 2002-07-12 | Oreal | Utilisation a ph acide de silicates mixtes en tant qu'agents tenseurs dans des compositions cosmetiques anti-rides |
ES2228467T3 (es) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
US6333054B1 (en) * | 1999-10-21 | 2001-12-25 | Amuchina S.P.A. | Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties |
JP2001240547A (ja) * | 2000-02-29 | 2001-09-04 | Lion Corp | 花粉症抑制剤 |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
WO2002064114A1 (en) * | 2001-02-15 | 2002-08-22 | Sanwa Kagaku Kenkyusho Co., Ltd. | Novel ophthalmic compositions |
AU2002246868B2 (en) | 2001-08-02 | 2007-05-31 | Johnson & Johnson Vision Care, Inc. | Antimicrobial lenses and methods of their use |
WO2003059263A2 (en) | 2001-12-21 | 2003-07-24 | Alcon, Inc. | Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions. |
PL211494B1 (pl) | 2001-12-21 | 2012-05-31 | Alcon | Zastosowanie syntetycznych, nieorganicznych nanocząstek jako nośników dla leków i kompozycja farmaceutyczna do oczu lub uszu |
US7217853B2 (en) * | 2002-05-24 | 2007-05-15 | Corium International, Inc. | Composition for cushions, wound dressings and other skin-contacting products |
DE60326597D1 (de) * | 2002-06-05 | 2009-04-23 | Univ Florida | Ophthalmisches arzneimittelabgabesystem |
US20050181015A1 (en) * | 2004-02-12 | 2005-08-18 | Sheng-Ping (Samuel) Zhong | Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles |
US20060193787A1 (en) * | 2005-01-31 | 2006-08-31 | Si-Shen Feng | Nanoparticle-based drug delivery system |
-
2002
- 2002-12-20 PL PL374262A patent/PL211494B1/pl unknown
- 2002-12-20 MX MXPA04004919A patent/MXPA04004919A/es active IP Right Grant
- 2002-12-20 SI SI200230922T patent/SI1474109T1/sl unknown
- 2002-12-20 ES ES02806507T patent/ES2349235T3/es not_active Expired - Lifetime
- 2002-12-20 CN CNB028253639A patent/CN100441169C/zh not_active Expired - Fee Related
- 2002-12-20 US US10/494,709 patent/US20050003014A1/en not_active Abandoned
- 2002-12-20 DE DE60237475T patent/DE60237475D1/de not_active Expired - Lifetime
- 2002-12-20 KR KR1020047009782A patent/KR100990810B1/ko not_active IP Right Cessation
- 2002-12-20 JP JP2003559360A patent/JP2005514429A/ja active Pending
- 2002-12-20 WO PCT/US2002/041248 patent/WO2003059194A2/en active Application Filing
- 2002-12-20 EP EP02806507A patent/EP1474109B1/de not_active Expired - Lifetime
- 2002-12-20 DK DK02806507.6T patent/DK1474109T3/da active
- 2002-12-20 PT PT02806507T patent/PT1474109E/pt unknown
- 2002-12-20 AU AU2002367029A patent/AU2002367029B2/en not_active Ceased
- 2002-12-20 AT AT02806507T patent/ATE478657T1/de active
- 2002-12-20 CA CA2467763A patent/CA2467763C/en not_active Expired - Fee Related
- 2002-12-20 BR BR0215238-0A patent/BR0215238A/pt not_active Application Discontinuation
-
2004
- 2004-05-13 ZA ZA2004/03666A patent/ZA200403666B/en unknown
-
2005
- 2005-08-22 HK HK05107301.4A patent/HK1075001A1/xx not_active IP Right Cessation
-
2011
- 2011-07-19 US US13/186,108 patent/US8257745B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ZA200403666B (en) | 2005-07-27 |
CN1604770A (zh) | 2005-04-06 |
PL374262A1 (en) | 2005-10-03 |
US8257745B2 (en) | 2012-09-04 |
CA2467763C (en) | 2011-09-13 |
EP1474109B1 (de) | 2010-08-25 |
BR0215238A (pt) | 2005-05-31 |
KR100990810B1 (ko) | 2010-10-29 |
AU2002367029A1 (en) | 2003-07-30 |
EP1474109A2 (de) | 2004-11-10 |
ES2349235T3 (es) | 2010-12-29 |
EP1474109A4 (de) | 2006-03-29 |
WO2003059194A2 (en) | 2003-07-24 |
CN100441169C (zh) | 2008-12-10 |
KR20040072669A (ko) | 2004-08-18 |
SI1474109T1 (sl) | 2010-11-30 |
US20050003014A1 (en) | 2005-01-06 |
JP2005514429A (ja) | 2005-05-19 |
PT1474109E (pt) | 2010-10-25 |
PL211494B1 (pl) | 2012-05-31 |
DK1474109T3 (da) | 2010-10-25 |
WO2003059194A3 (en) | 2004-05-13 |
US20110274760A1 (en) | 2011-11-10 |
CA2467763A1 (en) | 2003-07-24 |
HK1075001A1 (en) | 2005-12-02 |
AU2002367029B2 (en) | 2008-10-02 |
DE60237475D1 (de) | 2010-10-07 |
MXPA04004919A (es) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE478657T1 (de) | Verwendung von synthetischen anorganischen nanoteilchen als träger für augenmedikamente | |
WO2003059263A3 (en) | Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions. | |
DE60231682D1 (de) | Naturkautschuk-Masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung | |
DE60327994D1 (de) | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften | |
ATE319684T1 (de) | Sulfonamidderivate, deren herstellung und deren verwendung als medikamente | |
ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
DE60023520D1 (de) | Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung | |
DE60023919D1 (de) | Verbesserte topische zusammensetzungen mit extrazellulären produkten von probiotischen bakterien und verwendungen davon | |
DE602004015210D1 (de) | Nanoskalige Metalloxidpartikel | |
DE602004000926D1 (de) | Antimikrobielle Glaszusammensetzung und diese enthaltende antimikrobielle Polymerzusammensetzung | |
BG64475B1 (bg) | Ципразидонови соли | |
DE602004012083D1 (de) | Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren | |
ATE422880T1 (de) | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen | |
ATE448769T1 (de) | Abgabe von hydrogel-zusammensetzungen aus feinsprühnebel | |
DE60327693D1 (de) | Topische zusammensetzung enthaltend ein cyclofructan, einen träger und einen arzneistoff | |
AR036199A1 (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas | |
AR020532A1 (es) | Hidrogeles opticamente transparentes y procesos para su produccion. | |
DE502004008705D1 (de) | Klimabeständiger kosmetischer komplex | |
FR2825273B1 (fr) | Composition pour le traitement des signes cutanes du vieillissement | |
ATE417519T1 (de) | Tauchgeformte ärztliche instrumente aus cis-1,4- polyisopren | |
DE60016581D1 (de) | Funktionalisiertes polymer von glykosaminoglycan, arzneimittel und medizinische instrumente zu seiner herstellung | |
ATE414525T1 (de) | Homöpathisches mittel zur prophylaxe gegen von parasiten hervorgerufenen krankheiten | |
FR2885812B1 (fr) | Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique | |
ATE272642T1 (de) | Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel | |
DE69911989D1 (de) | Flüssige, in organischem glass mit guten optischen und physico-mechanischen eigenschaften, polymerisierbare kompositionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1474109 Country of ref document: EP |